Lean Mass Loss Offsets Any Potential GLP-1 Benefits in Strength-Dependent Sports

Healthline reporting and expert commentary highlight theoretical advantages in insulin sensitivity and body fat reduction, yet overlook primary trial data from the STEP and SURMOUNT programs published in NEJM. Those RCTs recorded average losses of 6.9 kg lean mass alongside 15-20 kg total weight, directly relevant to power output in cycling and combat sports. Observational athlete anecdotes remain unblinded and lack pre-post dynamometry or VO2 max measurements.

WADA criteria require demonstrated performance enhancement plus health risk or spirit violation. Current evidence meets none: no RCTs exist in trained populations, and muscle catabolism raises injury risk rather than conferring advantage. Policy discussions therefore rest on surrogate composition changes rather than functional outcomes.

Sports federations should await controlled crossover trials measuring repeated sprint ability and force production before any monitoring thresholds. Absent such data, legitimate therapeutic use for obesity or diabetes cannot be restricted on fairness grounds.